Gene · 780
Papers2,465
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,465
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). | J Transl Med | 2023 | 37475035 | PubTator, text mining | PubMed |
| RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer. | Breast Cancer Res | 2023 | 37461077 | PubTator, text mining | PubMed |
| Albuminuria-Related Genetic Biomarkers: Replication and Predictive Evaluation in Individuals with and without Diabetes from the UK Biobank. | Int J Mol Sci | 2023 | 37446387 | PubTator, text mining | PubMed |
| Identifying potential risk genes and pathways for neuropsychiatric and substance use disorders using intermediate molecular mediator information. | Front Genet | 2023 | 37415601 | PubTator, text mining | PubMed |
| Reciprocal discoidin domain receptor signaling strengthens integrin adhesion to connect adjacent tissues. | Elife | 2023 | 37405383 | PubTator, text mining | PubMed |
| Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells. | Cancer Res | 2023 | 37403628 | PubTator, text mining | PubMed |
| PAX5-miR-142 feedback loop promotes breast cancer proliferation by regulating DNMT1 and ZEB1. | Mol Med | 2023 | 37403081 | PubTator, text mining | PubMed |
| Ultra High-plex Spatial Proteogenomic Investigation of Giant Cell Glioblastoma Multiforme Immune Infiltrates Reveals Distinct Protein and RNA Expression Profiles. | Cancer Res Commun | 2023 | 37377888 | PubTator, text mining | PubMed |
| Evidence That DDR1 Promotes Oligodendrocyte Differentiation during Development and Myelin Repair after Injury. | Int J Mol Sci | 2023 | 37373466 | PubTator, text mining | PubMed |
| Reviewing the Regulators of COL1A1. | Int J Mol Sci | 2023 | 37373151 | PubTator, text mining | PubMed |
| Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling. | Signal Transduct Target Ther | 2023 | 37369642 | PubTator, text mining | PubMed |
| A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. | Front Med (Lausanne) | 2023 | 37358999 | PubTator, text mining | PubMed |
| Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors. | Transl Oncol | 2023 | 37354638 | PubTator, text mining | PubMed |
| Epigenetic modification in Parkinson's disease. | Front Cell Dev Biol | 2023 | 37351278 | PubTator, text mining | PubMed |
| Remyelination in multiple sclerosis from the miRNA perspective. | Front Mol Neurosci | 2023 | 37333618 | PubTator, text mining | PubMed |
| A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer. | J Immunother Cancer | 2023 | 37328286 | PubTator, text mining | PubMed |
| Genetic and epigenetic background of diabetic kidney disease. | Front Endocrinol (Lausanne) | 2023 | 37324271 | PubTator, text mining | PubMed |
| Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis. | Front Oncol | 2023 | 37324026 | PubTator, text mining | PubMed |
| A recombinant technique for mapping functional sites of heterotrimeric collagen helices: Collagen IV CB3 fragment as a prototype for integrin binding. | J Biol Chem | 2023 | 37302550 | PubTator, text mining | PubMed |
| Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR). | Int J Mol Sci | 2023 | 37298401 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/780/papers?page=17